MX391651B - Derivados de heteroarilo biciclico como potenciadores de cftr. - Google Patents
Derivados de heteroarilo biciclico como potenciadores de cftr.Info
- Publication number
- MX391651B MX391651B MX2019007135A MX2019007135A MX391651B MX 391651 B MX391651 B MX 391651B MX 2019007135 A MX2019007135 A MX 2019007135A MX 2019007135 A MX2019007135 A MX 2019007135A MX 391651 B MX391651 B MX 391651B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- cftr
- disubstituted
- amine derivatives
- cystic fibrosis
- Prior art date
Links
- 239000003623 enhancer Substances 0.000 title 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 abstract 4
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- -1 1,3-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine Chemical class 0.000 abstract 3
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435253P | 2016-12-16 | 2016-12-16 | |
| PCT/US2017/066317 WO2018112149A1 (en) | 2016-12-16 | 2017-12-14 | Bycyclic heteroaryl derivatives as cftr potentiators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019007135A MX2019007135A (es) | 2019-11-18 |
| MX391651B true MX391651B (es) | 2025-03-21 |
Family
ID=62557188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007135A MX391651B (es) | 2016-12-16 | 2017-12-14 | Derivados de heteroarilo biciclico como potenciadores de cftr. |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10131670B2 (enExample) |
| EP (1) | EP3554506B1 (enExample) |
| JP (1) | JP7150721B2 (enExample) |
| CN (1) | CN110300589B (enExample) |
| AU (2) | AU2017378324B2 (enExample) |
| CA (1) | CA3046968A1 (enExample) |
| MX (1) | MX391651B (enExample) |
| RU (1) | RU2753056C2 (enExample) |
| SG (2) | SG10201911221RA (enExample) |
| WO (1) | WO2018112149A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60906B1 (sr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu |
| EA201890913A1 (ru) | 2015-11-25 | 2018-11-30 | Джилид Аполло, Ллс | Пиразоловые соединения в качестве ингибиторов акк и их применение |
| EA201890949A1 (ru) | 2015-11-25 | 2018-12-28 | Джилид Аполло, Ллс | СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ |
| AU2016359626A1 (en) | 2015-11-25 | 2018-05-17 | Gilead Apollo, Llc | Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno(2,3-d)pyrimidine |
| KR20180082557A (ko) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | 트리아졸 acc 억제제 및 그의 용도 |
| LT3519401T (lt) | 2016-09-30 | 2021-11-25 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas |
| MX2021012639A (es) | 2016-11-18 | 2022-10-03 | Cystic Fibrosis Found | Pirrolopirimidinas como potenciadores de cftr. |
| PT3551622T (pt) | 2016-12-09 | 2020-11-12 | Vertex Pharma | Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2019018395A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | METHODS OF TREATING CYSTIC FIBROSIS |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| CA3085006A1 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| CA3088577A1 (en) | 2018-02-15 | 2019-08-22 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| EP3980121A1 (en) * | 2019-06-10 | 2022-04-13 | Novartis AG | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
| CN114007616A (zh) | 2019-07-15 | 2022-02-01 | 诺华股份有限公司 | (s)-3-氨基-6-甲氧基-n-(3，3，3-三氟-2-羟基-2-甲基丙基)-5-(三氟甲基)吡啶甲酰胺的配制品 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
| JP7784041B2 (ja) * | 2020-04-07 | 2025-12-11 | アイテオ ベルギウム エスエー | がんの治療のためのｅｎｔ阻害剤としての大環状ジアミン誘導体、及びそれとアデノシン受容体拮抗薬との組合せ |
| WO2022036060A1 (en) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| IL300405A (en) | 2020-08-20 | 2023-04-01 | Univ Leland Stanford Junior | Methods for treating respiratory diseases characterized by excessive secretion of mucus |
| US12612416B2 (en) | 2020-10-07 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL303519A (en) | 2020-12-10 | 2023-08-01 | Vertex Pharma | Cystic fibrosis treatment methods |
| CN112876524B (zh) * | 2021-01-26 | 2022-10-28 | 上海法默生物科技有限公司 | 一种瑞德西韦中间体的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| KR101461680B1 (ko) | 2005-12-02 | 2014-11-19 | 바이엘 헬스케어 엘엘씨 | 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체 |
| TW200801008A (en) * | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
| EA200870409A1 (ru) * | 2006-04-04 | 2009-04-28 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Антагонисты киназы pi3 |
| CN101917999A (zh) * | 2007-11-07 | 2010-12-15 | 弗尔德里克斯制药股份有限公司 | 蛋白质运输的调节 |
| KR101793304B1 (ko) * | 2010-02-05 | 2017-11-02 | 아드베리오 파마 게엠베하 | 낭성 섬유증의 치료를 위한, 단독으로의 및 ＰＤＥ5 억제제와 조합된 ｓＧＣ 자극제 또는 ｓＧＣ 활성화제 |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| CA2915418C (en) * | 2013-07-02 | 2022-05-03 | Rhizen Pharmaceuticals Sa | Novel selective pi3k delta and/or gamma protein kinase inhibitors |
| MX2021012639A (es) | 2016-11-18 | 2022-10-03 | Cystic Fibrosis Found | Pirrolopirimidinas como potenciadores de cftr. |
-
2017
- 2017-12-14 WO PCT/US2017/066317 patent/WO2018112149A1/en not_active Ceased
- 2017-12-14 CA CA3046968A patent/CA3046968A1/en active Pending
- 2017-12-14 AU AU2017378324A patent/AU2017378324B2/en active Active
- 2017-12-14 MX MX2019007135A patent/MX391651B/es unknown
- 2017-12-14 JP JP2019531417A patent/JP7150721B2/ja active Active
- 2017-12-14 CN CN201780086700.9A patent/CN110300589B/zh active Active
- 2017-12-14 SG SG10201911221RA patent/SG10201911221RA/en unknown
- 2017-12-14 EP EP17879832.8A patent/EP3554506B1/en active Active
- 2017-12-14 SG SG10201911076QA patent/SG10201911076QA/en unknown
- 2017-12-14 RU RU2019120990A patent/RU2753056C2/ru active
- 2017-12-14 US US15/841,902 patent/US10131670B2/en active Active
-
2018
- 2018-09-17 US US16/132,894 patent/US10208053B2/en active Active
- 2018-09-17 US US16/132,960 patent/US10377762B2/en active Active
-
2019
- 2019-07-09 US US16/506,883 patent/US10766904B2/en active Active
-
2021
- 2021-12-02 AU AU2021277702A patent/AU2021277702B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7150721B2 (ja) | 2022-10-11 |
| EP3554506B1 (en) | 2021-04-28 |
| US10131670B2 (en) | 2018-11-20 |
| CA3046968A1 (en) | 2018-06-21 |
| RU2019120990A3 (enExample) | 2021-01-18 |
| US20190330219A1 (en) | 2019-10-31 |
| SG10201911076QA (en) | 2020-01-30 |
| US10377762B2 (en) | 2019-08-13 |
| US20180170938A1 (en) | 2018-06-21 |
| MX2019007135A (es) | 2019-11-18 |
| AU2017378324B2 (en) | 2021-09-02 |
| CN110300589A (zh) | 2019-10-01 |
| CN110300589B (zh) | 2023-03-10 |
| AU2021277702B2 (en) | 2023-11-30 |
| JP2020502103A (ja) | 2020-01-23 |
| RU2019120990A (ru) | 2021-01-18 |
| AU2021277702A1 (en) | 2021-12-23 |
| AU2017378324A1 (en) | 2019-06-27 |
| US20190016728A1 (en) | 2019-01-17 |
| EP3554506A4 (en) | 2020-06-10 |
| RU2753056C2 (ru) | 2021-08-11 |
| EP3554506A1 (en) | 2019-10-23 |
| US10208053B2 (en) | 2019-02-19 |
| SG10201911221RA (en) | 2020-02-27 |
| BR112019012335A2 (pt) | 2020-03-03 |
| US10766904B2 (en) | 2020-09-08 |
| WO2018112149A1 (en) | 2018-06-21 |
| US20190016727A1 (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022201816A8 (en) | Pyrrolopyrimidines as CFTR potentiators | |
| MX2019007135A (es) | Derivados de heteroarilo biciclico como potenciadores de cftr. | |
| BR112018007161A2 (pt) | pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso | |
| BR112018007145A2 (pt) | ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso | |
| PH12018500088A1 (en) | Substituted tricyclics and method of use | |
| PH12021551196A1 (en) | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
| EP4606377A3 (en) | Novel amino pyrimidine derivatives | |
| WO2015042078A3 (en) | Substituted aminopyrimidine compounds and methods of use | |
| MX2014000338A (es) | Derivados de pirrolo-pirimidina novedoso. | |
| AU2018256602A1 (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| MX377175B (es) | Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc). | |
| NO20092067L (no) | 5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander | |
| BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase | |
| WO2014085494A8 (en) | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases | |
| Ding | Selective DDRs inhibitors as novel therapeutic agents for human cancers and pulmonary fibrosis | |
| DOP2003000724A (es) | Derivados de azol-pirimidina condensados | |
| UA95966C2 (en) | 5,7-disubstituted[1,3]thiazolo[4,5]pyrimidin-2(3h)-amine derivatives and their use in therapy |